Synthesis, In vivo, and In silico Evaluation of New Pyrazoline‐Benzothiazole Conjugates as Antiepileptic Agents

Abstract

AbstractNew 2‐(4‐benzothiazol‐2‐yl‐phenoxy)‐1‐(3,5‐diphenyl‐4,5‐dihydro‐pyrazol‐1‐yl)‐ethanones (9a–o) have been designed and synthesized. All the synthesized compounds were characterized by thin layer chromatography and spectral analysis. The antiepileptic potential of the synthesized compounds has been tested by following standard animal screening models, including maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) models. The neurotoxic and antidepression effects of the synthesized compounds were checked by utilizing rotarod apparatus, and motor impairment test (by actophotometer) respectively. The study concluded that compounds 9c, 9d, 9f, 9i, 9n, and 9o possessed good antiepileptic potential compared to standard drugs like carbamazepine and phenytoin. The results of the rotarod performance test also established them without any neurotoxicity. The motor impairment test revealed that the synthesized compounds are also good antidepressants. In‐silico studies have been performed for calculation of pharmacophore pattern, prediction of pharmacokinetic properties which determine the eligibility of synthesized compounds as orally administered molecules and interactions with the target proteins. The result of in‐silico studies reinforced results obtained by in vivo study of the synthesized compounds and their possible mechanism of antiepileptic action i. e. via inhibiting voltage‐gated sodium channels (VGSCs) and gamma‐aminobutyric acid‐A receptor.